Abstract | OBJECTIVE: DESIGN: Prospective randomized single-blind clinical trial. PARTICIPANTS: INTERVENTION: MAIN OUTCOME MEASURES: Changes in retinochoroidal lesion size after 6 weeks' treatment, visual acuity (VA) before and after intervention, adverse drug reactions during follow-up, and rate of recurrence. RESULTS: Active toxoplasmosis retinochoroiditis resolved in all patients over 6 weeks' treatment, with no significant difference in mean reduction of retinochoroidal lesion size between the 2 treatment groups (61% reduction in the classic treatment group and 59% in the trimethoprim/sulfamethoxazole group, P = 0.75). Similarly, no significant difference was found in VA after treatment between the 2 groups (mean VAs after treatment were 0.12 logarithm of the minimum angle of resolution [logMAR] [20/25] in the classic treatment group and 0.09 logMAR [20/25] in the trimethoprim/sulfamethoxazole group, P = 0.56). Adverse effects were similar in both groups, with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 24 months' follow-up was 10.16%, with no significant difference between the treatment groups (P = 0.64). CONCLUSIONS:
|
Authors | Masoud Soheilian, Mohammad-Mehdi Sadoughi, Mehdi Ghajarnia, Mohammad H Dehghan, Shahin Yazdani, Hassan Behboudi, Arash Anisian, Gholam A Peyman |
Journal | Ophthalmology
(Ophthalmology)
Vol. 112
Issue 11
Pg. 1876-82
(Nov 2005)
ISSN: 1549-4713 [Electronic] United States |
PMID | 16171866
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Protozoan
- Antiprotozoal Agents
- Immunoglobulin G
- Immunoglobulin M
- Sulfadiazine
- Trimethoprim, Sulfamethoxazole Drug Combination
- Pyrimethamine
|
Topics |
- Adolescent
- Adult
- Animals
- Antibodies, Protozoan
(blood)
- Antiprotozoal Agents
(therapeutic use)
- Child
- Chorioretinitis
(drug therapy, physiopathology)
- Drug Therapy, Combination
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Immunoglobulin G
(analysis)
- Immunoglobulin M
(analysis)
- Male
- Middle Aged
- Prospective Studies
- Pyrimethamine
(therapeutic use)
- Recurrence
- Single-Blind Method
- Sulfadiazine
(therapeutic use)
- Toxoplasma
(immunology)
- Toxoplasmosis, Ocular
(drug therapy, physiopathology)
- Treatment Outcome
- Trimethoprim, Sulfamethoxazole Drug Combination
(therapeutic use)
- Visual Acuity
|